REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results on Wednesday, May 4, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at 5:00 p.m. ET (2:00 p.m. PT).
The live conference call may be accessed by phone by dialing (866) 410-4428 (domestic) or (704) 908-0287 (international), conference code 1388773.
To access the live and subsequently archived webcast, visit the investor relations section of the Relypsa website at http://investor.relypsa.com. The webcast will be archived for 30 days following the call.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Vice President, Corporate Communications